Research Papers:
Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2552 views | HTML 2991 views | ?
Abstract
Sang-Yong Shin1, Seung-Tae Lee2, Hee-Jin Kim3, Eun Hae Cho5, Jong-Won Kim3, Silvia Park4, Chul Won Jung4, Sun-Hee Kim3
1Department of Laboratory Medicine, Center for Diagnostic Oncology, Hospital and Research Institute, National Cancer Center, Goyang, Korea
2Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
3Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
5Green Cross Genome, Yongin, Korea
Correspondence to:
Seung-Tae Lee, email: [email protected]
Sun-Hee Kim, email: [email protected]
Keywords: acute myeloid leukemia, mutation, next generation sequencing, DNMT3A
Received: October 19, 2015 Accepted: May 13, 2016 Published: June 23, 2016
ABSTRACT
We selected 19 significantly-mutated genes in AMLs, including FLT3, DNMT3A, NPM1, TET2, RUNX1, CEBPA, WT1, IDH1, IDH2, NRAS, ASXL1, SETD2, PTPN11, TP53, KIT, JAK2, KRAS, BRAF and CBL, and performed massively parallel sequencing for 114 patients with acute myeloid leukemias, mainly including those with normal karyotypes (CN-AML). More than 80% of patients had at least one mutation in the genes tested. DNMT3A mutation was significantly associated with adverse outcome in addition to conventional risk stratification such as the European LeukemiaNet (ELN) classification. We observed clinical usefulness of mutation testing on multiple target genes and the association with disease subgroups, clinical features and prognosis in AMLs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10240